In Brief: Paclitaxel environmental assessments
Paclitaxel environmental assessments: Required in INDs, NDAs and ANDAs for paclitaxel products "derived from or otherwise involving the Pacific yew," FDA states in Nov. 18 Federal Register. Assessments should identify sources of Pacific yew, impacts of harvest, measures to mitigate adverse impacts and reasonable alternatives...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth